Almac has expanded its pharmaceutical development service offering with an investment of more than $10 million. The company has doubled its development service capabilities with the opening of a new dedicated non-GMP facility and two analytical laboratories at its UK headquarters.
The new non-GMP formulation development facility offers formulation and process development, which can then be progressed and transferred to the existing GMP development facility located on the same campus. Almac has also doubled its analytical capacity with new analytical labs for processing the large sample sets from non-GMP process development work for clients looking to better understand their processes in line with the principles of QbD. Almac has also invested in additional Xcelodose technology, which comes with an Xcelohood providing the capability to dose potent API directly into capsules.
“Almac is continually assessing and investing in solutions to accelerate the manufacturing of our client’s clinical supplies, while ensuring quality at all times. The investments this year in the new non-GMP facility and Xcelodose equipment strengthens Almac’s position as an integrated service provider in the pharmaceutical development sector,” said John McQuaid, vice president of Technical Operations.